457 related articles for article (PubMed ID: 29453313)
21. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
[No Abstract] [Full Text] [Related]
22. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
23. Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
Zhang T; Armstrong AJ
Curr Oncol Rep; 2016 Jan; 18(1):3. PubMed ID: 26700506
[TBL] [Abstract][Full Text] [Related]
24. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
[TBL] [Abstract][Full Text] [Related]
25. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
26. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
28. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
29. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer.
Zavridou M; Smilkou S; Tserpeli V; Sfika A; Bournakis E; Strati A; Lianidou E
Clin Chem; 2022 Oct; 68(10):1323-1335. PubMed ID: 36093578
[TBL] [Abstract][Full Text] [Related]
30. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
31. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.
Miyamoto DT; Lee RJ; Kalinich M; LiCausi JA; Zheng Y; Chen T; Milner JD; Emmons E; Ho U; Broderick K; Silva E; Javaid S; Kwan TT; Hong X; Dahl DM; McGovern FJ; Efstathiou JA; Smith MR; Sequist LV; Kapur R; Wu CL; Stott SL; Ting DT; Giobbie-Hurder A; Toner M; Maheswaran S; Haber DA
Cancer Discov; 2018 Mar; 8(3):288-303. PubMed ID: 29301747
[TBL] [Abstract][Full Text] [Related]
32. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
34. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
Danila DC; Anand A; Schultz N; Heller G; Wan M; Sung CC; Dai C; Khanin R; Fleisher M; Lilja H; Scher HI
Eur Urol; 2014 Jun; 65(6):1191-7. PubMed ID: 23954088
[TBL] [Abstract][Full Text] [Related]
35. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
[TBL] [Abstract][Full Text] [Related]
36. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
Zhang Z; Luo R; Kelly WK; Chen J; Donahue S; Ip K; Handley NR; Tester WJ; Tsang ML; Kim FJ; Myers R; Lu-Yao G; Gu J; Lin J; Li B; Wang C; Yang H
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):339-347. PubMed ID: 38057610
[TBL] [Abstract][Full Text] [Related]
37. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
38. Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies.
Ma Y; Luk A; Young FP; Lynch D; Chua W; Balakrishnar B; de Souza P; Becker TM
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27527157
[TBL] [Abstract][Full Text] [Related]
39. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Groen L; Kloots I; Englert D; Seto K; Estafanos L; Smith P; Verhaegh GW; Mehra N; Schalken JA
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
